What is Bright Biotech?
Bright Biotech operates as a Contract Manufacturing and Development Organization (CMDO) with a specialized focus on plant-based expression systems. The company is dedicated to the high-quality and cost-effective production of recombinant proteins. These proteins serve a diverse range of applications, spanning research and development, therapeutic uses, cosmeceuticals, agri-food industries, and broader industrial sectors. Their expertise in leveraging plant-based platforms positions them as a key player in the biomanufacturing landscape, offering an alternative to traditional protein production methods.
How much funding has Bright Biotech raised?
Bright Biotech has raised a total of $3.2M across 1 funding round:
Angel/Seed
$3.2M
Angel/Seed (2022): $3.2M with participation from CPT Capital, FoodLabs, and Big Idea Ventures
Key Investors in Bright Biotech
CPT Capital
CPT Capital is an investment firm focused on the future of food and materials, specifically in the alternative protein sector. They partner with visionary founders and companies that utilize cutting-edge technologies to replace animals in the supply chain.
FoodLabs
FoodLabs is a Berlin-based firm dedicated to backing innovative companies focused on improving planetary and human health through food technology. They support entrepreneurs in creating iconic products like animal-free cheese, guilt-free meat, and sustainable soft drinks.
Big Idea Ventures
Big Idea Ventures is a venture capital fund and startup accelerator focused on addressing global food challenges by investing in innovative companies in the food tech sector. Their Global Food Innovation Fund and accelerator program support startups developing alternative proteins, ingredients, and sustainable food solutions.
What's next for Bright Biotech?
The substantial enterprise-level funding and strategic investment Bright Biotech has recently garnered signal a pivotal growth phase for the company. This capital infusion is expected to accelerate its expansion, likely enabling enhancements in production capacity, further research into novel protein applications, and the scaling of its proprietary plant-based expression technology. The company is poised to solidify its market position and potentially explore new verticals within the biopharmaceutical and industrial biotechnology sectors, driven by its commitment to innovation and sustainable protein manufacturing.
See full Bright Biotech company page
